Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ClaraCeed Ultra
- Development stage
- Preclinical
- Lead developer
- Colcare Laboratories
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
**ClaraCeed Ultra** is a proprietary, orally administered full-spectrum medical-cannabis tablet developed and manufactured by Columbia Care. It is a precisely dosed, long-lasting, hard-pressed tablet containing an ultra-high cannabidiol concentration as its primary active constituent, reported to be nearly three times that of standard ClaraCeed tablets, together with 11 additional functional cannabinoids. ClaraCeed Ultra was studied as adjunctive treatment for pediatric and adult patients with drug-resistant intractable epilepsy, with evaluation of safety, tolerability, and potential reduction of convulsive seizures. Its therapeutic activity is attributed to the pharmacology of cannabidiol and the broader cannabis-derived cannabinoid mixture, but a single established molecular mechanism for the proprietary formulation has not been publicly defined.
- Brand names
- ClaraCeed Ultra
Beyond the preview
Go deeper on ClaraCeed Ultra.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ClaraCeed Ultra.